| scholarly article | Q13442814 |
| P50 | author | Yehuda Shoenfeld | Q1515807 |
| Gerard Espinosa | Q60326205 | ||
| Gisele Zandman-Goddard | Q73268900 | ||
| Ricard Cervera i Segura | Q53547424 | ||
| P2093 | author name string | E B González | |
| D Erkan | |||
| M Solomon | |||
| A R Cabral | |||
| M G Tektonidou | |||
| H E Adrogué | |||
| S Vadya | |||
| P2860 | cites work | CEREBRO-VASCULAR LESIONS AND LIVEDO RETICULARIS | Q28201845 |
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients | Q33329596 | ||
| Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study | Q33338827 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission | Q33364647 | ||
| Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? | Q33367182 | ||
| Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis | Q33368167 | ||
| The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome | Q33369426 | ||
| The ‘Primary’ Antiphospholipid Syndrome: Antiphospholipid Antibody Pattern and Clinical Features of a Series of 23 Patients | Q33371184 | ||
| The antiphospholipid antibody syndrome in the emergency department setting — Livedo reticularis and recurrent venous thrombosis | Q33374702 | ||
| Microvascular and microangiopathic antiphospholipid-associated syndromes ("MAPS"): semantic or antisemantic? | Q33378245 | ||
| The hematologic manifestations of the antiphospholipid syndrome | Q33379294 | ||
| Antiphospholipid antibodies in adults with immune thrombocytopenic purpura | Q33379770 | ||
| The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe | Q33385759 | ||
| The geoepidemiology of the antiphospholipid antibody syndrome | Q33387143 | ||
| Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study | Q33390708 | ||
| Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder | Q33433089 | ||
| Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes | Q33448386 | ||
| (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura | Q33449588 | ||
| Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody | Q33459225 | ||
| Anticardiolipin antibodies in autoimmune thrombocytopenic purpura | Q33459994 | ||
| Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects | Q33490868 | ||
| Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice | Q33491319 | ||
| Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study | Q33494721 | ||
| Antiphospholipid syndrome and the skin | Q33499667 | ||
| Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome | Q33500479 | ||
| Characterization of beta2-glycoprotein I-dependent and -independent "antiphospholipid" antibodies from lupus-prone NZW/BXSB F1 hybrid male mice. | Q33500487 | ||
| The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review | Q34560515 | ||
| Antiphospholipid syndrome: pathogenic mechanisms | Q35172006 | ||
| Cutaneous manifestations of antiphospholipid antibody syndrome | Q37061152 | ||
| Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis | Q38553245 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis | Q45126748 | ||
| Sneddon's syndrome: generalized livedo reticularis and cerebrovascular disease. Importance of hemostatic screening | Q46712557 | ||
| Anetoderma and its prothrombotic abnormalities | Q47363407 | ||
| Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? | Q54098585 | ||
| P433 | issue | 2 | |
| P921 | main subject | thrombocytopenia | Q585285 |
| catastrophic antiphospholipid syndrome | Q5051580 | ||
| P304 | page(s) | 174-181 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations | |
| P478 | volume | 20 |
| Q92639094 | Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery |
| Q64046338 | Antiphospholipid syndrome |
| Q42732341 | Antiphospholipid syndrome-associated nephropathy: Current concepts |
| Q33412407 | Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications |
| Q33394969 | Clinical assessment and management of cytopenias in lupus patients |
| Q64075728 | Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome |
| Q33423959 | Current treatment of antiphospholipid syndrome: lights and shadows |
| Q33421814 | Difficult clinical situations in the antiphospholipid syndrome |
| Q33397398 | Immune thrombocytopenia with antiphospholipid antibodies in monozygotic twins |
| Q33436927 | Lupus anticoagulant hypoprothrombinemia syndrome associated with severe thrombocytopenia in a child |
| Q33401971 | Management of myocardial infarction in immune thrombocytopenic purpura with anti-phospholipid antibodies |
| Q38033398 | Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. |
| Q59791491 | Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome |
| Q41980805 | Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report |
| Q33429418 | Refractory Immunological Thrombocytopenia Purpura and Splenectomy in Pregnancy |
| Q33420910 | The significance and management of thrombocytopenia in antiphospholipid syndrome |
| Q33443108 | Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study |
| Q33419495 | Vascular- and pregnancy-related outcomes in patients with systemic lupus erythematosus with positive antiphospholipid profile and thrombocytopenia |
Search more.